Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.57 |
| ▸ | TACR3 | P29371 | 4/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497210 | 0.84 | P2RX7 (0.46) | P2RX7TACR3 | |
| SCHEMBL22683927 | 0.84 | P2RX7 (0.56) | P2RX7TACR3PDK2KRASCYP2C19 | |
| SCHEMBL31447391 | 0.80 | P2RX7 (0.52) | P2RX7TACR3KRAS | |
| SCHEMBL3135974 | 0.76 | DPP4 (0.55) | DPP4DPP8 | |
| SCHEMBL25239634 | 0.75 | P2RX7 (0.51) | P2RX7TACR3PDK2DPP4KCNH2 | |
| SCHEMBL26123625 | 0.75 | P2RX7 (0.40) | P2RX7TACR3PDK2DPP4DPP8 | |
| SCHEMBL572678 | 0.75 | PDK2 (0.46) | P2RX7TACR3PDK2DPP4DPP8 | |
| SCHEMBL107690 | 0.74 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL1017946 | 0.72 | P2RX7 (0.54) | P2RX7TACR3PDK2 | |
| SCHEMBL9931417 | 0.71 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062486-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| CN-114630822-A | Biaryl dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| EP-2892890-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | Cancer Research Technology Ltd (GB) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037751-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2424869-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062486-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | KRAS, NRAS, HRAS | P2RX7 3986/4885TACR3 4244/4885PDK2 1894/4885 |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | P2RX7 1/4885TACR3 94/4885PDK2 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.